ERBB2 and cancer: Molecular subtypes, in fact, can affect the response to NAC; HER2+ and TNBC cancers have a higher probability of responding well to preoperative therapy, but, on the other hand, patients with nonluminal disease have worse recurrence-free and disease-specific survival [64].